Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Disease Burden of the Most Common Autoimmune Diseases.

Managed care (Langhorne, Pa.)·2017
Same author

Effect of Removing Financial Barriers on Use Of Long-acting Reversible Contraceptives.

Managed care (Langhorne, Pa.)·2017
Same author

William B. White Explains the Changes In the Way We Look at Blood Pressure: Which Numbers Matter Most-and Why Can They Be Deceptive?

P & T : a peer-reviewed journal for formulary management·2016
Same author

Prediabetes: Pre- Does Not Mean Preordained.

Managed care (Langhorne, Pa.)·2016
Same author

First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Kenneth tanabe works to solve the mysteries of liver cancer: while progress has been relatively slow, this noted expert sees reasons for hope.

P & T : a peer-reviewed journal for formulary management·2015

Related Experiment Video

Updated: Feb 27, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Chimeric Antigen Receptor T-Cell Therapy: The Next Big Thing Faces Challenges.

Jack McCain

    Managed Care (Langhorne, Pa.)
    |June 30, 2017
    PubMed
    Summary

    Chimeric antigen receptor T cell (CAR T) therapy shows promise for cures, but challenges like resistance and cytokine release syndrome persist. Further research aims to improve CAR T cell production and durability for lasting responses.

    Area of Science:

    • Immunotherapy
    • Cellular Therapy
    • Oncology

    Background:

    • Chimeric antigen receptor T cells (CAR T) represent a significant advancement in cancer treatment.
    • The potential for CAR T therapy to achieve durable remissions is being explored, with some researchers discussing the possibility of a "cure".

    Purpose of the Study:

    • To explore the potential of CAR T cell modularity in overcoming treatment resistance.
    • To investigate strategies for converting initial complete responses into long-term, lasting complete responses.
    • To identify and address key challenges in CAR T cell therapy.

    Main Methods:

    • Analysis of CAR T cell modular design principles.
    • Review of current approaches to combatting CAR T cell resistance.
    • Evaluation of methods for enhancing CAR T cell production efficiency.

    More Related Videos

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
    09:12

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

    Published on: June 14, 2024

    1.5K
    Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
    08:09

    Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

    Published on: March 14, 2025

    1.7K

    Related Experiment Videos

    Last Updated: Feb 27, 2026

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
    09:56

    A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

    Published on: February 21, 2025

    1.5K
    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
    09:12

    Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

    Published on: June 14, 2024

    1.5K
    Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
    08:09

    Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

    Published on: March 14, 2025

    1.7K

    Main Results:

    • The modular nature of CAR T cells offers potential for novel strategies against resistance.
    • Addressing challenges like cytokine release syndrome and resistance is crucial for improving treatment outcomes.
    • Efficient production methods are needed to broaden accessibility.

    Conclusions:

    • CAR T cell therapy holds significant promise for cancer treatment, potentially leading to cures.
    • Overcoming resistance and managing toxicities are key areas for future development.
    • Improving manufacturing processes is essential for wider clinical application.